The peculiarities of course and treatment of pulmonary tuberculosis with initial drug resistance

D. Krasnov, V. Krasnov, S. Naryshkina, A. Andrenko, V. Potashova (Novosibirsk, Russia)

Source: Annual Congress 2003 - Management and resistance features in tuberculosis
Session: Management and resistance features in tuberculosis
Session type: Poster Discussion
Number: 377
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Krasnov, V. Krasnov, S. Naryshkina, A. Andrenko, V. Potashova (Novosibirsk, Russia). The peculiarities of course and treatment of pulmonary tuberculosis with initial drug resistance. Eur Respir J 2003; 22: Suppl. 45, 377

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018



Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001

Treatment results in patients with drug resistant pulmonary tuberculosis
Source: Eur Respir J 2002; 20: Suppl. 38, 612s
Year: 2002

The clinical features and treatment results of cases with multidrug resistant pulmonary tuberculosis
Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis
Year: 2004


Association of genetic markers with clinical course of patients with pulmonary tuberculosis with drug resistance
Source: Eur Respir J 2007; 30: Suppl. 51, 203s
Year: 2007

Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre
Source: Eur Respir J 2003; 22: Suppl. 45, 524s
Year: 2003

Primary drug resistance in pulmonary tuberculosis
Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases
Year: 2007


Primary drug resistance rates in pulmonary tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 42s
Year: 2003

Clinical characteristic of the patients with drug resistant pulmonary tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007

Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 197s
Year: 2007

Monitoring of drug resistance of TB mycobacteria in new pulmonary TB patients
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010

A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis
Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis
Year: 2007


Frequency of development acquired drug resistance in successful treated patients with newly detected pulmonary tuberculosis
Source: Eur Respir J 2002; 20: Suppl. 38, 612s
Year: 2002

Development of mycobacterium tuberculosis additional drug resistance during chemotherapy of disseminated pulmonary tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 663s
Year: 2007

Predicting outcomes and drug resistance with standardised treatment of active tuberculosis
Source: Eur Respir J 2010; 36: 870-877
Year: 2010



Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis?
Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis
Year: 2008

The evaluation of the relapse or treatment interrupted pulmonary tuberculosis cases
Source: Eur Respir J 2006; 28: Suppl. 50, 21s
Year: 2006

Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017
Year: 2017



Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017
Year: 2017



The ratios of primary and secondary drug resistance in pulmonary tuberculosis
Source: Eur Respir J 2002; 20: Suppl. 38, 361s
Year: 2002